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Background: Hyperinflation is a recognized adverse prognostic factor in COPD. As the sniff
inspiratory nasal pressure (SnIP) principally reflects the severity of hyperinflation in COPD,
we hypothesized that it might also be a predictor of mortality. We therefore compared the
SnIP to the inspiratory capacity-to-total lung capacity (IC/TLC) ratio as predictors of mortality
in advanced COPD.
Methods: A retrospective mortality analysis of 110 patients with COPD (mean FEV1 1.01 litres,
37% predicted; 66% male) was performed. All patients had SnIP and lung volume measurements
performed. The power of each test to predict mortality was determined, and predicted
survival curves were created for both the SnIP and IC/TLC ratio.
Results: 37 patients (34%) died during the study period (29 male, 8 female). Mortality rates were
analysedwith aChi2 test; therewas a significant trend towardsmale death (mortality ratemale vs.
female; 39.7% vs. 21.6% respectively; c2 pZ 0.058, Chi 3.6). ROC curves demonstrated that both
SnIP and IC/TLC ratio are predictors of mortality, but analysis by Cox proportional hazards sug-
gested the SnIP has a stronger predictive power (SnIP vs. IC/TLC ratio; pZ 0.017 vs 0.525; HR
0.97 vs 0.99 respectively), and analysis of the area under ROC curves (AUC) suggest that SnIP is
a better discriminator than IC/TLC ratio (AUC SnIP vs IC/TLC; 0.679 vs 0.618).
Conclusions: The SnIP conveys at least as much predictive power for mortality in COPD as hyper-
inflation determined by IC/TLC ratio. This test is cheaper, quicker and easier thanmeasuring lung
volumes by plethysmography.
ª 2010 Published by Elsevier Ltd.976 924582; fax: þ44 207 351 8939.
(A.J. Moore).
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1320 A.J. Moore et al.Background Pulmonary function and body mass index (BMI) calcula-The variability in the long term outcome of patients with
Chronic Obstructive Pulmonary Disease (COPD) can lead to
uncertainties in prognosis and survival. There have been
extensive studies looking at the ability to stratify patients
into groups that carry a survival prediction and a variety of
parameters have been described to predict mortality in
COPD.1 These include 6 minute walking test,2 cardiopul-
monary exercise testing3,4 body mass index5,6 and quadri-
ceps strength.7 The BODE Index has been described which
combines four separate indices and has also been demon-
strated to be a strong predictor of mortality in COPD.8
Recently, Casanova et al.9 demonstrated that pulmonary
hyperinflation in COPD, measured as the inspiratory
capacity-to-total lung capacity (IC/TLC) ratio, was an
independent risk factor for mortality. The measurement of
lung volumes to calculate this ratio, however, requires
whole body plethysmography with expensive apparatus,
moderately complex procedures and training and at least
some patient coordination.
It has previously been shown that the principal cause of
the reduced inspiratory muscle strength in COPD is hyper-
inflation10 and interventions which reduce hyperinflation,
such as bronchodilators11 or lung volume reduction proce-
dures,12,13 improve diaphragm function in a remarkably
constant way with the diaphragm strength, determined as
the twitch transdiaphragmatic pressure (TwPdi), typically
rising by approximately 4 cmH2O per litre reduction in lung
volume towards predicted functional residual capacity
(FRC). The maximal sniff inspiratory nasal pressure (SnIP) is
a well recognised tool for the assessment of inspiratory
muscle strength,14 and so this measurement does reflect
the degree of hyperinflation in COPD.15 The hypothesis that
the SnIP, as a surrogate for hyperinflation, is a useful
predictor of mortality in patients with advanced COPD is
tested here. If true, this technique would have some
advantages over plethysmographically determined lung
volumes, particularly the ease of the manoeuvre and the
size, cost and portability of the apparatus.
The present study describes a mortality analysis in
a cohort of patients with COPD and determines the
predictive power of the SnIP value compared to the degree
of hyperinflation determined by IC/TLC ratio.
Methods
A retrospective mortality analysis of patients who had
attended the Respiratory Muscle Laboratory of the Royal
Brompton Hospital for respiratory muscle tests was per-
formed. Patients with COPD, diagnosed according to the
GOLD criteria16,17 who were regular follow-up attendees at
the Outpatients department of the hospital had been invited
to visit the Muscle Laboratory for full pulmonary function
testing and simple respiratory muscle testing as part of
previous studies.18,19 These individuals were identified and
a questionnaire sent to their primary care physician to
ascertain the mortality status of the patient. The primary
endpoint of the studywas time to death, calculated from the
datewhen the SnIP test and lung volumemeasurementswere
performed, until the date of analysis of patient data.tions had been performed in all patients on the same day as
the respiratory muscle studies. Spirometry was obtained
using the best effort measured by a digital spirometer, lung
volumes measured by whole body plethysmography and gas
transfer by a single breath technique (CompactLab System,
Jaeger, Germany).20 Reference values were taken from the
1993 ERS statement for lung function testing, and adjusted
according to ethnic origin.21
Measuring sniff pressure was achieved by wedging
a pressure catheter moulded around a bung made of dental
putty in one nostril. This was connected to pressure
transducers and the subject sniffed through the contralat-
eral nostril. In general, several attempts were needed to
reach optimum technique and the pressure obtained in the
obstructed nostril reflects the pressure in the nasopharynx,
which is a reasonable indicator of alveolar pressure.
The pressure transducers were Validyne DP45 differen-
tial pressure transducers (Validyne Co., Northridge, CA,
USA) which had a range of 150 to þ300 cmH2O, and were
calibrated against atmosphere using a 2 point calibration
system with a Bio-Tek hand-held pressure meter (Bio-Tek
Instruments, Winooski, VT, USA). The pressure signals were
amplified (Validyne Co., Northridge, CA, USA), digitised via
a DAQ-6036E card (National Instruments, Austin, Tx, USA)
and passed into a desktop computer (Hewlett Packard, CA,
USA) running a modified version of LabView software
(National Instruments, Austin, Tx, USA). The performance
of the Bio-Tek meter itself was found to be accurate and
linear when compared to a mercury manometer. At least 5
attempts at the SnIP were performed for every patient
using both visual and verbal encouragement.
A Cox proportional hazards model was used to test
the independent effects of various possible prognostic
pulmonary function measurements on the hazard (i.e.: the
endpoint, death). Significance was assumed if the p value
was <0.05. Visually, these were represented by Receiver
Operating Characteristic (ROC) curves and measurement
of the area under the ROC curve (AUC) was used to
compare how powerful each test was to predict survival.
Kaplan-Meier survival curves of all-cause mortality were
created to show the cumulative probability of survival at
any point after the baseline. Individuals who were still
alive at the time of analysis were right-censored.
Comparisons between the baseline anthropometric char-
acteristics in the survivor and non-survivor groups were
performed with either a two-sample t-test, or Chi-square
(c2) test. All data are expressed as means (SD) unless
otherwise stated.Results
In total 133 patients were identified, and mortality data
was available on 110 (73 male:37 female), e representing
83% of the total. Median follow up time between date of
test and date of endpoint was 1367 days (range 19e2300
days). During this follow up period there were 37 deaths
(34%; 29 male:8 female). Baseline characteristics for all
individuals, and separated into survivors and non-survivors
are shown in Table 1. Differences in lung volumes between
the survivors and non-survivors are illustrated in Table 2.
Table 1 Baseline anthropometric and pulmonary function characteristics.
Variable Total (nZ 110) Alive (nZ 73) Dead (nZ 37)
Age, years 62.8 (9.4) 61.2 (9.2) 65.9 (9.1)a
Height, cm 169.6 (8.7) 169.6 (8.5) 169.6 (9.2)
Weight, kg 72.4 (19.7) 72.1 (18.1) 73.1 (22.8)
BMI, kg/m2 25.1 (6.3) 25.1 (6.2) 25 (6.4)
M/F ratio 73/37 44/29 29/8
FEV1, litres 1.01 (0.5) 1.1 (0.5) 0.9 (0.4)
FEV1, % predicted 36.6 (18.2) 38.2 (19.8) 33.4 (14.3)
FEV1/FVC, % 33.7 (13.2) 34.9 (14) 31.4 (11.1)
GOLD Stage
I (80% of % predicted FEV1), n(%) 2 (1.8) 2 (2.7) 0 (0)
II (50e80% of % predicted FEV1), n(%) 21 (19.1) 17 (23.3) 4 (10.8)
III (30e50% of % predicted FEV1), n(%) 37 (33.6) 23 (31.5) 14 (37.8)
IV (<30% of % predicted FEV1), n(%) 50 (45.5) 31 (42.5) 19 (51.4)
Patients also separated into survivors and non-survivors. BMI body mass index, M/F ratio male:female ratio, FEV1 forced expiratory
volume in 1 second, FVC forced vital capacity. All values are means (1SD).
a p< 0.05 between survivors and non-survivors.
SnIP and mortality in COPD 1321Individuals who died were older, had more severe COPD
according to GOLD criteria16 and more severe hyperinfla-
tion judged by a lower IC/TLC ratio. They also had more
damaged lungs as judged by a lower transfer factor (TLCO
and KCO). The mortality rates for men and women were
analysed with a Chi2 test. This showed that there was
a significant trend towards male death rather than female,
with 39.7% of the men versus 21.6% of the women dying (c2;
pZ 0.058, Chi 3.6). When the mortality rates were ana-
lysed according to severity of COPD using a c2 test for trend
there was, as expected, a trend for increased mortality
with increasing severity of disease although this did not
reach statistical significance (pZ 0.1). The Kaplan-Meier
analysis for all cause mortality is shown in Fig. 1.Table 2 Lung volume and muscle strength measurements





SnIP, cm H2O 67.7 (19.4) 54.7 (18.9)
a
TLC, litres 7.6 (1.7) 7.9 (1.6)
TLC, % predicted 125.3 (17.0) 127.1 (20.4)
RV, litres 4.6 (1.4) 4.9 (1.3)
RV, % predicted 207.9 (58.3) 213.0 (63.7)
RV/TLC, % 59.5 (10.5) 61.9 (9.9)
RV/TLC, % predicted 156.9 (31.4) 158.8 (31.3)
FRC, litres 5.5 (1.6) 6.0 (1.4)
FRC % predicted 172.0 (41.0) 182.4 (37.8)
IC, litres 2.1 (1.0) 1.9 (0.7)
IC/TLC, % 28.1 (10.7) 23.7 (7.5)a
TLCOc 3.9 (1.8) 2.7 (1.3)a
TLCOc, %predicted 45.4 (21.3) 31.6 (14.9)a
KCOc 0.9 (0.4) 0.6 (0.3)a
KCOc %predicted 56.2 (25.7) 40.6 (18.2)a
TLC total lung capacity, RV residual volume, FRC functional
residual capacity, IC inspiratory capacity, TLCOc carbon
monoxide gas transfer corrected for Hb, KCO gas transfer cor-
rected for lung volume.
a p< 0.05 between survivors and non-survivors.Of the individuals who died, based on the knowledge
that IC/TLC ratio is a predictor of mortality, the correlation
between this and other variables which could be considered
as predictors of mortality were analysed with a Cox
proportional hazards model. Individually, IC/TLC ratio,
TLCO % predicted, and Sniff Inspiratory Nasal Pressure were
all significant prognosticators of mortality (Cox propor-
tional hazards; all p< 0.05). Neither FRC % predicted, RV/
TLC ratio, BMI nor FEV1 % predicted were significant
predictors of mortality (all p> 0.05).
Multi-variate analysis of the IC/TLC ratio, TLCO % pre-
dicted and SnIP together, using the Cox model, showed that
in the presence of all 3 variables only the TLCO % predicted
was a significant predictor of mortality (TLCO %p;
pZ 0.048, HR 0.98, CI 0.95e0.99). The SnIP was nearly
significant (SnIP; pZ 0.065, HR 0.98, CI 0.96e1.0), but the
IC/TLC ratio was not significant (IC/TLC; pZ 0.61, HR 1.0,
CI 0.97e1.05). However, when comparing the SnIP and IC/
TLC ratio together, only the sniff test was significantly
associated with mortality (SnIP vs. IC/TLC ratio; pZ 0.017
vs 0.525; HR 0.97 vs 0.99 respectively).Figure 1 Kaplan Meier analysis of all cause mortality (Total
cohort of 110 COPD patients (bold line) and 95% CI are
illustrated ).
Figure 2 ROC curves comparing predictive power of SnIP and
IC/TLC.
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the IC/TLC ratio are illustrated in Fig. 2. Whilst both curves
lie to the left of the diagonal, the AUC for the SnIP is greater
than for the IC/TLC ratio (AUC SnIP vs IC/TLC; 0.679 vs
0.618), suggesting again that SnIP may be a better discrim-
inator of outcomes than IC/TLC. If this is compared to other
measures of hyperinflation, for example FRC % predicted or
RV/TLC ratio, it can be seen that the SnIP is a more powerful
test that either of these parameters (Fig. 3).Figure 3 ROC curves comparing predictive power of SnIP
versus A: FRC %predicted and B: RV/TLC.Analysis of the ROC curves AUC data is illustrated in
Table 3. This data suggests that, although IC/TLC remains
a good predictor, the SnIP is the better discriminator
compared with the other variables of hyperinflation.
Predicted survival curves were also created for a range
of SnIP and IC/TLC ratio values (Figs. 4 and 5), to illustrate
the comparative power of the two measurements. The
ranges in these graphs equate to approximately the
mean 1SD for the values of both the SnIP (43, 63 and
83 cmH2O) and the IC/TLC ratio (16, 26 and 36%) in the
cohort. These graphs show that a change of 1SD in the value
of the SnIP brings about a larger change in predicted
survival than the equivalent change in IC/TLC ratio.Discussion
The results of the present study show that the SnIP is
certainly as powerful, and may even be a superior predictor
of mortality in COPD compared to the IC/TLC ratio. Any
change in the magnitude of the SnIP was associated with
a larger change in mortality than a comparative change in
IC/TLC ratio. This is important, given the comparative ease
and cost-effectiveness of measuring the SnIP compared to
the IC/TLC ratio. This study also identified the TLCO %
predicted, a parameter not used in current prognostic tools
for COPD, as a significant marker of mortality in this
disease.
Measurement of respiratory muscle strength can be
achieved either during voluntary manoeuvres (volitional),
such as the sniff nasal pressure, or during involuntary
contraction of the muscles (non-volitional) elicited by
electrical or magnetic stimulation. In both cases the force
created by the respiratory muscles is estimated by the
change of pressure in different body compartments during
contraction of the muscles. These pressures are therefore
markers of the respiratory muscle output, rather than
direct measures of their contractile properties.14 Sniff
nasal pressure is a simple, painless easy test and is a per-
formed by a short sharp voluntary inspiratory manoeuvre
through an unoccluded nostril. This creates a coordinated
contraction of the diaphragm and other inspiratory muscles
which provides a similar or greater measure of trans-
diaphragmatic pressure than maximal inspiratory efforts.22
In the present study, the primary outcome measure was
assessed by means of a questionnaire sent to the patients’
primary care physicians. This questionnaire did not specify
the cause of death and so the data reflect all cause
mortality. The cohort of patients analysed in this study
make up a representative sample of the population seen in
the hospital Outpatients department. As expected, the
majority of patients who are seen in a hospital clinic have
more severe disease with 79.1% of patients in GOLD stage III
or IV. This is indicative of the management of mild COPD by
primary care physicians and as a result this study was
unable to comment on prognostic markers for mild disease.
Taken as independent variables, as well as the IC/TLC
ratio, both the SnIP and TLCO % predicted were significantly
associated with mortality. It is not unexpected that the IC/
TLC ratio should be identified as a prognostic marker, in line
with the recent publication by Casanova,9 and it is likely
that the SnIP result is a reflection of the degree of
Table 3 Analysis of ROC curves data.
Parameter N AUC 95% CI
SnIP 110 0.679 0.573 0.785
IC/TLC Ratio 110 0.618 0.510 0.725
FRC, % pred 110 0.569 0.456 0.683
RV/TLC, % 110 0.557 0.447 0.668
Figure 5 Predicted Kaplan Meier survival curves for IC/TLC
ratio.
SnIP and mortality in COPD 1323hyperinflation and thus this significance mirrors that of IC/
TLC. However, an interesting feature of this study was that
other measures of hyperinflation such as RV/TLC ratio e
a marker of gas trapping in COPD e was not significantly
associated with mortality. Furthermore, multivariate anal-
ysis of SnIP and IC/TLC ratio considered alone actually
suggest that the SnIP is superior to IC/TLC ratio at pre-
dicting mortality (pZ 0.017 vs 0.52 respectively).
It is well known that in COPD patients SnIP measure-
ments tend to underestimate the sniff oesophageal pres-
sure (SnPoes)23 and as a result underestimate respiratory
muscle strength. This results from dampening of the pres-
sure transmission between the alveoli and mouth due to
changes in both airway resistance and upper airway
compliance. In addition intrinsic positive end-expiratory
pressure (PEEPi) in severe COPD can change with dynamic
hyperinflation, referred to as dynamic PEEP (PEEPi,dyn).
During an inspiratory manoeuvre, before a change in the
airway opening pressure, there is a change in pleural
pressure representing the change in pressure required to
overcome this PEEPi,dyn. Both of these mechanisms may
reduce the ability of the SnIP to accurately predict respi-
ratory muscle strength. Whilst this conveys some limita-
tions in the use of this test alone for the assessment of
diaphragm strength in COPD, the changes in airways resis-
tance and compliance are themselves, in part, the sequelae
of lung hyperinflation. Paradoxically therefore, although
SnIP measurements may underestimate diaphragm strength
in COPD, this ‘underestimation’ may enhance the value of
the test as a prognostic indicator.
Although the SnIP is mainly determined by hyperinfla-
tion, the measurement is potentially susceptible to influ-
ences from other factors which are considered to influence
prognosis in COPD. In particular undernutrition and other
systemic factors (such as inflammation) reduce peripheral
muscle strength and worsen prognosis in COPD.5,24 It isFigure 4 Predicted Kaplan Meier survival curves for SnIP.known that these influences can in some circumstances
influence diaphragm structure and strength25,26 and it may
be that the SnIP measurement can detect this in individual
patients with emphysema, and in combination with the
pressure transmission issue discussed above, this may be
the reason why the SnIP was actually a superior predictor of
mortality to IC/TLC ratio in the present study.
The SnIP is a non-invasive volitional test and although it
is easy to measure, either the SnPoes or indeed the sniff
transdiaphragmatic pressure (SnPdi) could have been used
as an alternative which undoubtedly would have given
a more accurate measure of respiratory muscle strength.
Both the SnPoes and SnPdi, however, require the passage of
oesophageal and gastric balloon catheters which, although
easily tolerated in the majority of patients, detract from
the underlying principle of the present study which revolves
around the ease with which the SnIP measurement can be
made and the acceptability of the test by subject. The fact
that the SnIP emerged from the analysis as a strong
predictor of mortality suggest that these criticisms do not
detract from the usefulness of this measurement.
Dyspnoea scores and exercise data were not available
for the patients and so the BODE index score8 could not be
calculated; indeed the measurements started in 2001
before Celli et al. proposed their score. This prevented
a direct comparison of these results to the BODE scoring
system which is recognized as a powerful predictive tool.
However, the recent publication by Casanova et al.9
compared lung hyperinflation, as measured by the IC/TLC
ratio, to the BODE index and demonstrated that resting
hyperinflation is an additional independent risk factor for
mortality in COPD. The reported AUC values for BODE and
IC/TLC in Casanova’s study were 0.795 and 0.742 respec-
tively. Both these values are higher than the values repor-
ted here for SnIP (0.679) and IC/TLC ratio (0.618) which
presumably reflects differences in the cohorts studied.
Although Casanova et al. showed the IC/TLC ratio to be
an excellent predictor of mortality in COPD, the application
of this, to some extent, is limited by the need for specialist
lung function testing with plethysmography to provide lung
volume data. Not only is the equipment needed for these
measurements expensive, but they are time consuming and
require experienced technicians to perform them. Indeed,
in the UK at least, a recent survey showed that although
1324 A.J. Moore et al.89% of hospitals can provide lung volume measurements
using gas dilution, only 50% offer plethysmography e the
‘‘gold standard’’ means of lung volume measurement.27 An
interesting finding of this study was that multivariate
analysis of a number of parameters measured actually
showed that the IC/TLC ratio was not as strong a predictor
of mortality as has previously been thought when analysed
together with the SnIP and TLCO %predicted. In fact
a surprising result of this study suggest that the TLCO is
actually the better marker of survival than either the IC/
TLC ratio or SnIP. The knowledge that TLCO is a prognostic
marker in COPD has been available for over 50 years,28,29
and it is also used as a marker of suitability for lung
volume reduction surgery in COPD.30 Few studies, however,
suggest using TLCO as an independent predictor of survival
in COPD. Despite this, both Oga3 and Martinez1 have
recently found that again TLCO was independently associ-
ated with survival in COPD (p< 0.01 in both studies),
although the significance was weakened by multivariate
analysis with other prognostic parameters. Certainly the
current ‘‘best’’ model to predict survival in COPD, the BODE
Index8 incorporates neither TLCO nor any marker of
hyperinflation in the prediction score.
Conclusion
The purpose of this study was to explore the use of the SnIP
as a surrogate for hyperinflation in COPD, and thus
demonstrate its prognostic power in COPD in line with the
existing evidence on hyperinflation in COPD. The findings
presented here have potentially important clinical conse-
quences, as the ease and speed with which the sniff test
can be performed and the availability of relatively cheap
hand held sniff nasal meters (approximately £600),
compared to the expense and size of lung function labo-
ratory equipment (in the order of thousands of pounds)
means that the test could be performed by both primary
care physicians or by secondary care physicians in an
outpatient clinic, thereby rapidly identifying the most at-
risk patients. Although there is no dispute that pulmonary
function testing, with lung volumes and gas transfer
measurements, are an extremely important tool for the
assessment of patients with respiratory disease, the
measurement of the SnIP would add to the arsenal of tests
available to assess the mortality risk of patients with COPD
and provide an easy means of monitoring their disease
progress and prognosis. The SnIP may also prove useful in
research studies as a means of screening, to stratify cohorts
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